Drugs / TRIS(8-HYDROXYQUINOLINATO)GALLIUM
TRIS(8-HYDROXYQUINOLINATO)GALLIUM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04143789 | Sep 2019 → Mar 2021 | cancer | Altum Pharmaceuticals INC | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRIS(8-HYDROXYQUINOLINATO)GALLIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594524 ↗ |
| Known as | AP-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04143789 ↗ |
| Known as | Gallium, tris(8-quinolinolato)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594524 ↗ |
| Known as | IT-235 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594524 ↗ |
| Known as | LX-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594524 ↗ |
| Known as | NKP-2235 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594524 ↗ |
| Known as | NSC-158197 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594524 ↗ |
| Route | Oral | “Patients will receive AP-002 orally, once daily for 14 days of a 21 day cycle.” NCT04143789 ↗ |